Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Jan 31, 2024 | (FY)Dec 31, 2023 | (Q4)Oct 31, 2023 | (Q3)Jul 31, 2023 | (Q2)Apr 30, 2023 | (Q1)Jan 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 62.50%151.12M | 289.25%45.86M | 262.54%40.99M | 282.36%39.42M | 9.89%11.84M | 158.07%92.99M | 23.06%11.78M | 24.23%11.31M | 21.52%10.31M | 21.41%10.78M |
Operating revenue | 62.50%151.12M | 289.25%45.86M | 262.54%40.99M | 282.36%39.42M | 9.89%11.84M | 158.07%92.99M | 23.06%11.78M | 24.23%11.31M | 21.52%10.31M | 21.41%10.78M |
Cost of revenue | 152.70%62.54M | 122.98%19.07M | 102.68%18.59M | 114.95%17.73M | 1.61%8.47M | -7.90%24.75M | 14.67%8.55M | 38.54%9.17M | 38.81%8.25M | 21.62%8.33M |
Gross profit | 29.79%88.57M | 729.28%26.79M | 949.24%22.4M | 952.71%21.69M | 38.16%3.38M | 644.80%68.24M | 52.61%3.23M | -13.94%2.14M | -18.92%2.06M | 20.70%2.44M |
Operating expense | 55.91%84.47M | 1,148.45%25.53M | 672.30%23.38M | 745.27%21.56M | 11.69%3.1M | 504.00%54.18M | -46.41%2.05M | 72.82%3.03M | 43.14%2.55M | 71.10%2.77M |
Selling and administrative expenses | 49.38%78.1M | 836.80%19.16M | 672.30%23.38M | 745.27%21.56M | 11.69%3.1M | 482.84%52.28M | -46.41%2.05M | 72.82%3.03M | 43.14%2.55M | 71.10%2.77M |
-Selling and marketing expense | 55.25%18.93M | ---- | ---- | ---- | ---- | --12.19M | ---- | ---- | ---- | ---- |
-General and administrative expense | 47.59%59.17M | ---- | ---- | ---- | 11.69%3.1M | 346.94%40.09M | -46.41%2.05M | 72.82%3.03M | 43.14%2.55M | 71.10%2.77M |
Depreciation amortization depletion | 235.81%6.37M | ---- | ---- | ---- | ---- | --1.9M | ---- | ---- | ---- | ---- |
-Depreciation and amortization | 235.81%6.37M | ---- | ---- | ---- | ---- | --1.9M | ---- | ---- | ---- | ---- |
Operating profit | -70.83%4.1M | 6.20%1.26M | -9.45%-976.38K | 125.49%125.11K | 184.88%279.2K | 7,206.06%14.06M | 169.77%1.19M | -222.32%-892.1K | -164.69%-490.73K | -181.43%-328.96K |
Net non-operating interest income expense | -5,457.29%-3.3M | -26,467.45%-2.64M | -9,845.84%-731.72K | 129.80%37.18K | 254.49%38.66K | 570.91%61.66K | 35.00%10.01K | 846.78%7.51K | 2,885.24%16.18K | 2,373.24%10.91K |
Non-operating interest income | 123.01%218.15K | 322.49%55.12K | 286.43%58.48K | 311.74%69.67K | 229.81%39.26K | 964.42%97.82K | 75.98%13.05K | 1,808.20%15.13K | 3,021.77%16.92K | 2,599.55%11.91K |
Non-operating interest expense | 9,637.27%3.52M | 88,584.66%2.69M | 10,264.55%790.19K | 4,289.73%32.48K | -39.88%600 | --36.16K | --3.04K | --7.62K | --740 | --998 |
Other net income (expense) | -69.43%409.81K | -1,724.92%-751.17K | 588,397.87%276.59K | 2,787.57%378.3K | -6.91%18.82K | 412.77%1.34M | -220.81%-41.16K | -99.84%47 | -88.52%13.1K | -76.13%20.21K |
Gain on sale of security | -782.90%-494.83K | -282.01%-157.24K | -466,185.11%-219.06K | -1,103.42%-131.46K | -6.91%18.82K | -72.28%72.46K | -220.81%-41.16K | -99.84%47 | -88.52%13.1K | -76.13%20.21K |
Special income (charges) | -346.23%-1.36M | ---- | ---- | ---- | ---- | ---304.36K | ---- | ---- | ---- | ---- |
-Write off | 346.23%1.36M | ---- | ---- | ---- | ---- | --304.36K | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | 43.92%2.26M | --764.22K | --495.65K | --509.76K | ---- | --1.57M | ---- | ---- | ---- | ---- |
Income before tax | -92.19%1.21M | -284.63%-2.13M | -61.84%-1.43M | 217.15%540.6K | 213.04%336.69K | 3,239.75%15.47M | 169.63%1.15M | -216.60%-884.54K | -152.84%-461.45K | -160.90%-297.84K |
Income tax | 66.70%2.62M | -113.64%-52.42K | 2,199.00%1.86M | 626.09%524.97K | 79.96%262.18K | 274.83%1.57M | 313.54%384.24K | 2.70%81.08K | -57.91%72.3K | 93.21%145.69K |
Net income | -110.15%-1.41M | -369.93%-2.08M | -241.29%-3.3M | 102.93%15.63K | 116.80%74.51K | 31,459.20%13.89M | 143.99%770.15K | -242.08%-965.63K | -176.09%-533.75K | -207.22%-443.52K |
Net income continuous Operations | -110.15%-1.41M | -369.93%-2.08M | -241.29%-3.3M | 102.93%15.63K | 116.80%74.51K | 31,459.20%13.89M | 143.99%770.15K | -242.08%-965.63K | -176.09%-533.75K | -207.22%-443.52K |
Minority interest income | -63.40%70.4K | 51.48K | 109.94K | -49.3K | -34.59%192.35K | 0 | 0 | 0 | ||
Net income attributable to the parent company | -110.80%-1.48M | -376.61%-2.13M | -252.68%-3.41M | 112.16%64.93K | 116.80%74.51K | 5,580.18%13.7M | 142.44%770.15K | -253.68%-965.63K | -190.93%-533.75K | -226.95%-443.52K |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -110.80%-1.48M | -376.61%-2.13M | -252.68%-3.41M | 112.16%64.93K | 116.80%74.51K | 5,580.18%13.7M | 142.44%770.15K | -253.68%-965.63K | -190.93%-533.75K | -226.95%-443.52K |
Basic earnings per share | -106.25%-0.01 | -166.67%-0.02 | 0.00%-0.03 | 105.38%0.0005 | 120.54%0.0021 | 1,700.00%0.16 | 142.86%0.03 | -250.00%-0.03 | -150.00%-0.01 | -200.00%-0.01 |
Diluted earnings per share | -106.25%-0.01 | -166.67%-0.02 | 0.00%-0.03 | 105.05%0.0005 | 119.21%0.0019 | 1,700.00%0.16 | 142.86%0.03 | -250.00%-0.03 | -150.00%-0.01 | -200.00%-0.01 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |